About the author
Robert Boersma is Partner at Oaklins’ team in the Netherlands and leads the global healthcare team. As part of his healthcare sector focus, Robert continuously follows developments, publishes reports, attends the major events and maintains regular contact with the key players. Consequently, he has a deep understanding of the market dynamics and value drivers in this sector. Globally, Robert is the most experienced M&A advisor in the healthcare sector and is specialized in medical technology and device-related transactions.
Head of the global healthcare team
Robert and is a partner at Oaklins Netherlands. He has advised numerous healthcare clients on sell-side and buy-side M&A transactions and is experienced in fundraisings. Robert has completed transactions for or with companies such as Novartis, Alliance Medical, Mediq, Arseus, DSM, C.B. Fleet, Synthon, Gilde Healthcare Services, Pharmaline, Xendo and Tramedico. These transactions were related to pharmaceutical products, generics, compounding, pharmaceutical services, life sciences, active (pharmaceutical) ingredients (APIs), medical devices, med-tech and biotech (services). Prior to joining the team in 1999, Robert was finance manager at DSM N.V., a listed multinational life sciences and performance materials company, where he was involved in the strategy to quadruple DSM’s presence in fine chemicals via acquisitions.